Physician profile
Lance H Betson
NPI 1497834964
$8,445.74
in general payments reported to CMS, 2019-2025
26 companies · $487 in 2025
The $487 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Obstetrics & Gynecology) provider received nationally (typical 2025 total: $413).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $569 · 2020: $430 · 2021: $628 · 2022: $2,046 · 2023: $775 · 2024: $3,512 · 2025: $487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,062 · Food and Beverage: $1,697 · Gift: $14.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,061.95 |
| Food and Beverage | $1,696.59 |
| Gift | $14.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,881.09 | 2022-2024 | Da Vinci Surgical System |
| Medtronic, INC. | $604.33 | 2021-2023 | Interstim |
| Abbvie INC. | $503.98 | 2019-2025 | Botox |
| Medtronic USA, INC. | $446.74 | 2019-2020 | |
| Boston Scientific Corporation | $436.77 | 2022-2025 | Advantage System, Solyx Sis System |
| Pfizer INC. | $262.37 | 2019-2024 | |
| Allergan, INC. | $203.00 | 2020-2021 | |
| Astellas Pharma US INC | $197.42 | 2019-2023 | Myrbetriq |
| Ascend Therapeutics US, LLC | $146.70 | 2023 | |
| Mayne Pharma Commercial LLC | $121.82 | 2025 | |
| Sumitomo Pharma America, INC. | $121.57 | 2023 | Myfembree |
| Urocure LLC | $98.69 | 2020 | |
| Coopersurgical, INC. | $83.73 | 2019-2023 | Advincula Delineator Uterine Manipulator |
| Viiv Healthcare Company | $58.35 | 2023-2024 | Dovato |
| Axonics, INC. | $54.49 | 2023-2024 | Axonics, Bulkamid |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Femselect INC. | $35.71 | 2025 | Enplace |
| Caldera Medical, INC | $25.20 | 2021 | |
| Ethicon US, LLC | $23.41 | 2023 | Ethicon |
| Karl Storz Endoscopy-America | $23.04 | 2019 | |
| Vertical Pharmaceuticals, LLC | $21.06 | 2019 | |
| Tesaro, INC. | $19.62 | 2019 | |
| Hologic Sales and Service, LLC | $18.13 | 2019 | |
| Myovant Sciences INC. | $18.11 | 2021 | |
| Channel Medsystems, INC. | $14.95 | 2021 | |
| Urovant Sciences INC | $13.78 | 2022 | |
| Merck Sharp & Dohme LLC | $11.68 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Betson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.